{"name":"Pain Therapeutics","slug":"pain-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":41119000,"revenueGrowth":0,"grossMargin":0,"rdSpend":26590000,"netIncome":-90973000,"cash":118355000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPZzdnS3ptRkZ2b09zcS1EYjBsN0thQ21WdzlfbUpFa2VXS0trc2dVTjc3MGxVZW5ZMEFlTmJxX3AwUVYwU2hCMHZJdGJwUnRBSUZLUlF5S1drR3ZpaXRkaUw1NmtWRDFQU3VVZ0t2WVpPZHBacGcyNU1zZUtMYVFkODZvYWxjY29UQ1JiQVdJR28tODVzSU4tMzVLeHBSMDg2YUx2Yi1Bcm04WEgzX3c1blZQYTBReG9hdGc?oc=5","date":"2026-02-20","type":"pipeline","source":"The Pharma Letter","summary":"Global pain market presents significant opportunities for novel mechanisms - The Pharma Letter","headline":"Global pain market presents significant opportunities for novel mechanisms","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQY1JXMVkxV3dHZl9zdEJ1cjlHX09aMDJZeUt2VFllQXQ5bkk3NlhjSXBMUDdBWXdIajRKNFIxNm1samdfbVFQQk04TUNTXzBaSFFnNDdhZTBtaUtHdjI3ZG55dVB5LUNzSzZnbURkd2V1YlFZX3NnX1pTb0FnYk1zMG5FNFM3dlY1aTNMUWNMeHFtc3hSMFR0REFEM09nVkppVFVidndB?oc=5","date":"2026-02-13","type":"pipeline","source":"Pharmaceutical Technology","summary":"Significant opportunities exist in the global pain market for novel mechanisms and modalities - Pharmaceutical Technology","headline":"Significant opportunities exist in the global pain market for novel mechanisms and modalities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNOXVHMzhyaWpTREJ6OW1OQ2pXY1ZiRl8xcjhxb3pxaGJjN0ptZzA4cjFWRnFEa1kyazNyUUJRZ1V0Mnh2dHJpeWdxWGhoRWV0emstd3Y0SmlJdFdfZExlc3VBdlZjaU5PVWx1V1lpV2VRSmhsTXF6cGNjRlhiblQxOEVHVm51MFVyczBCMDhR?oc=5","date":"2026-01-30","type":"trial","source":"Yahoo Finance","summary":"Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - Yahoo Finance","headline":"Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxORndENnRrM1V5UHZ4VzU0Y2ZxcXhzYWZjNV9YZ2xKSEtkSmtJazRLWS1OeDFPaWhqalhSV3IwQ0x0UGpSeHdWcFRNSGFwM2Jlakd4bGVGWTYwTHlDS1R0a2RLZzlsOWhyU2s0U0dpSG9FVFl3SjlNQ2s1Tk1qQUtYelJ2VUdiMVZuWWxVWWxqT0h0TnNFbVdzVzdQc2pvaWo5RHh2WVhTclVGTy02Wi1nYXFhczRjdUhkSlBEVmtB?oc=5","date":"2026-01-30","type":"pipeline","source":"Stock Titan","summary":"After 15-year gap, new non-opioid fibromyalgia drug improves pain and sleep - Stock Titan","headline":"After 15-year gap, new non-opioid fibromyalgia drug improves pain and sleep","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNM3lIbEE5YkRhX3d0Umh5TDJteElEQjBKOFJva2RELWUwTWVzYmZJQ3R6X25yWFhHYkp4TEJRa05OOTM2b09ldm9Sd0hDamNPUzNXWGpZdUlTS1ZYYWdWZWJ1SXV4QW44YWMyclZzWEl2d3pQak9XWk5BelNUbXM2Z21Wbi1jQUd3UUtoWU93TTF0c18wSkZqUDhMQjlkWmpDcGxmQ09PdU9qNHlyT3NwQmlLZlpFLTJJYi1DR3NyNA?oc=5","date":"2025-12-16","type":"pipeline","source":"statnews.com","summary":"Ambros Therapeutics, Ramaswamy’s latest startup, launches with plans for pain treatment - statnews.com","headline":"Ambros Therapeutics, Ramaswamy’s latest startup, launches with plans for pain treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"deal","source":"Newswise","summary":"Rutgers Licenses Novel Pain Treatment Compound to Tonix Pharmaceuticals, Advancing Non-Opioid Solutions for Chronic Pain | Newswise - Newswise","headline":"Rutgers Licenses Novel Pain Treatment Compound to Tonix Pharmaceuticals, Advancing Non-Opioid Solutions for Chronic Pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUTRJTHpEU2gwQ2lCMUtnclNQc29ueGxONW9fb3NISXA5a0RTSVU0Nl9yRGtfdGFUUmppM0VTZ3RucTR2cDJzY2ZfX05zYU9aZ2JoZWRkMGI1eld4c1NVUDlUc0ZXMHh4UmpFU29hODYyVXI0Tm9JbU1wc1NTV01FbHB3NjVPbGx4eWI4MVlCSFlMYk1BY0JKdGMtSFNVOXdfZ2VQZGZiSHctUQ?oc=5","date":"2025-12-16","type":"pipeline","source":"Fierce Biotech","summary":"Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug - Fierce Biotech","headline":"Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":41119000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":41119000,"period":"2013-12-31"},{"value":41119000,"period":"2013-12-31"},{"value":41119000,"period":"2013-12-31"},{"value":35244000,"period":"2013-12-31"},{"value":35244000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26590000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-90973000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":118355000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}